Cumulative incidence of complete response (Hb ≥13 g/dL) (primary end point) from the day of treatment initiation. (A) All conditionings together; (B) after MA conditioning (Cohort 1), after NMHCT with rhEPO started on D28 (Cohort 2), and after NMHCT when rhEPO initiated on D0 (Cohort 3). The control arm is indicated by a solid line, and the EPO arm by a dotted line.